DOP2001000242A - PHENOXIBENCILAMINE DERIVATIVES AS SSRI - Google Patents

PHENOXIBENCILAMINE DERIVATIVES AS SSRI

Info

Publication number
DOP2001000242A
DOP2001000242A DO2001000242A DO2001000242A DOP2001000242A DO P2001000242 A DOP2001000242 A DO P2001000242A DO 2001000242 A DO2001000242 A DO 2001000242A DO 2001000242 A DO2001000242 A DO 2001000242A DO P2001000242 A DOP2001000242 A DO P2001000242A
Authority
DO
Dominican Republic
Prior art keywords
alkyl
heterocyclic ring
alkoxy
nitrogen
independently
Prior art date
Application number
DO2001000242A
Other languages
Spanish (es)
Inventor
Mavis Diane Adam
Mark David Andrews
Mark Leonard Elliott
Geoffrey Edward Gymer
David Hepworth
Harry Ralph Howard Jr
Donald Stuart Middleton
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0021593A external-priority patent/GB0021593D0/en
Priority claimed from GB0107116A external-priority patent/GB0107116D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2001000242A publication Critical patent/DOP2001000242A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Un compuesto de fórmula general (l) en la que R1 y R2 son H, alquilo C1-C6 o (CH2)d-(cicloalquilo C3-C6), donde d es O, 1, 2 ó 3; o R1 y R2 junto con el nitrógeno al que están unidos forman un anillo de azetidina; uno de Z o Y es -SR3 y el otro de Z o y es halógeno o -R3 donde R3 es independientemente alquilo C1-C4 opcionalmente sustituido con flúor; excepto que R3 no es CF3 o Z e y están unidos de manera que, junto con los átomos de interconexión, Z e y forman un anillo carbocíclico o heterocíclico de 5 a 7 miembros, condensado, y donde, cuando Z e y forman un anillo heterocíclico, además de átomos de carbono, el enlace contiene uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; R4 y R5, que pueden ser iguales o diferentes, son: A-X, donde A es -CH=CH- o -(CH2) donde p es 0, 1 ó 2 X es hidrógeno, F, Cl, Br, l, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, alcoxi C1-4, NR8SO2R9, N02, NR6R11, CN, C02R10 , CHO, SR10 SOR9 ó S02R10 ; o un anillo heterocíclico de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados entre N, S y O, opcionalmente sustituido independientemente con uno o más R13 donde R13 es hidroxi, alcoxi C1-C4, F, alquilo C1-C6, haloalquilo, haloalcoxi, -NH2, -NH(alquilo C1-C6) o -N(alquilo C1-C6) 2.A compound of the general formula (1) in which R 1 and R 2 are H, C 1 -C 6 alkyl or (CH 2) d- (C 3 -C 6 cycloalkyl), where d is O, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; one of Z or Y is -SR3 and the other of Z or y is halogen or -R3 where R3 is independently C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3 or Z and y are linked so that, together with the interconnecting atoms, Z ey form a 5 to 7 membered carbocyclic or heterocyclic ring, and where, when Z ey form a heterocyclic ring, in addition of carbon atoms, the bond contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: AX, where A is -CH = CH- or - (CH2) where p is 0, 1 or 2 X is hydrogen, F, Cl, Br, l, CONR6R7, SO2NR6R7, SO2NHC (= O) R6, OH, C1-4 alkoxy, NR8SO2R9, N02, NR6R11, CN, C02R10, CHO, SR10 SOR9 or S02R10; or a 5 or 6 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally independently substituted with one or more R13 where R13 is hydroxy, C1-C4 alkoxy, F, C1-C6 alkyl, haloalkyl, haloalkoxy, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl) 2.

DO2001000242A 2000-08-31 2001-08-29 PHENOXIBENCILAMINE DERIVATIVES AS SSRI DOP2001000242A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0021593A GB0021593D0 (en) 2000-08-31 2000-08-31 Diphenyl ether compounds useful in therapy
GB0107116A GB0107116D0 (en) 2001-03-21 2001-03-21 Novel compounds

Publications (1)

Publication Number Publication Date
DOP2001000242A true DOP2001000242A (en) 2002-05-15

Family

ID=26244953

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000242A DOP2001000242A (en) 2000-08-31 2001-08-29 PHENOXIBENCILAMINE DERIVATIVES AS SSRI

Country Status (32)

Country Link
EP (1) EP1313701A1 (en)
JP (1) JP2004507523A (en)
KR (1) KR20030029889A (en)
CN (1) CN1449380A (en)
AP (1) AP2001002265A0 (en)
AR (1) AR031867A1 (en)
AU (1) AU2001278650A1 (en)
BG (1) BG107544A (en)
BR (1) BR0113610A (en)
CA (1) CA2420969A1 (en)
CZ (1) CZ2003467A3 (en)
DO (1) DOP2001000242A (en)
DZ (1) DZ3414A1 (en)
EA (1) EA200300206A1 (en)
EE (1) EE200300084A (en)
HN (1) HN2001000191A (en)
HR (1) HRP20030141A2 (en)
HU (1) HUP0303385A2 (en)
IL (1) IL154343A0 (en)
IS (1) IS6704A (en)
MA (1) MA26945A1 (en)
MX (1) MXPA03001848A (en)
NO (1) NO20030842L (en)
NZ (1) NZ523951A (en)
OA (1) OA12372A (en)
PA (1) PA8526701A1 (en)
PE (1) PE20020346A1 (en)
PL (1) PL360743A1 (en)
SK (1) SK2012003A3 (en)
TN (1) TNSN01131A1 (en)
UY (1) UY26924A1 (en)
WO (1) WO2002018333A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
JP3997255B2 (en) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Androgen receptor modulator
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
BRPI0513020A (en) 2004-07-08 2008-04-22 Warner Lambert Co androgen modulators, their uses, pharmaceutical composition, topical pharmaceutical formulation and article of manufacture
MX2007001993A (en) * 2004-08-18 2007-05-10 Warner Lambert Co Androgen modulators.
EP1791807A1 (en) * 2004-09-10 2007-06-06 Pfizer Products Incorporated Therapeutic diphenyl ether ligands
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
US7939528B2 (en) 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
CA2656075A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
CA2656089A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
CN101511790A (en) * 2006-06-29 2009-08-19 詹森药业有限公司 Substituted aminomethyl benzamide compounds
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
WO2010059390A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
KR101043200B1 (en) * 2010-11-08 2011-06-21 성시민 Air charging device for respiration air tank
GB2501206B (en) 2011-01-27 2019-12-04 Hewlett Packard Development Co A computing device to connect to a portable device
US20220185815A1 (en) 2019-03-06 2022-06-16 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
EP0714391A1 (en) * 1993-08-19 1996-06-05 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
CZ293595A3 (en) * 1995-11-09 1999-12-15 Farmak A. S. Derivatives of n,n-dimethyl-2-(arylthio)benzylamine, their salts, processes of their preparation and their use in medicaments
EP1071648A2 (en) * 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
NZ512910A (en) * 1999-02-23 2003-11-28 Pfizer Prod Inc Monoamine reuptake inhibitors for treatment of CNS disorders
GB0007884D0 (en) * 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy

Also Published As

Publication number Publication date
PE20020346A1 (en) 2002-05-08
MA26945A1 (en) 2004-12-20
EP1313701A1 (en) 2003-05-28
PA8526701A1 (en) 2003-07-28
EA200300206A1 (en) 2003-06-26
JP2004507523A (en) 2004-03-11
OA12372A (en) 2006-04-17
NZ523951A (en) 2004-09-24
CA2420969A1 (en) 2002-03-07
IL154343A0 (en) 2003-09-17
MXPA03001848A (en) 2003-06-04
UY26924A1 (en) 2002-03-22
CZ2003467A3 (en) 2004-04-14
EE200300084A (en) 2005-02-15
BG107544A (en) 2003-10-31
KR20030029889A (en) 2003-04-16
HRP20030141A2 (en) 2003-04-30
IS6704A (en) 2003-01-30
NO20030842D0 (en) 2003-02-24
PL360743A1 (en) 2004-09-20
WO2002018333A1 (en) 2002-03-07
TNSN01131A1 (en) 2005-11-10
HUP0303385A2 (en) 2004-03-01
BR0113610A (en) 2003-06-24
CN1449380A (en) 2003-10-15
AR031867A1 (en) 2003-10-08
HN2001000191A (en) 2002-03-11
NO20030842L (en) 2003-04-28
AP2001002265A0 (en) 2001-09-30
AU2001278650A1 (en) 2002-03-13
SK2012003A3 (en) 2004-06-08
DZ3414A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
DOP2001000242A (en) PHENOXIBENCILAMINE DERIVATIVES AS SSRI
AR038723A1 (en) USEFUL ROADS AS BIOMARKERS
BRPI0506817A (en) selective kinase inhibitors
CR8505A (en) DERIVATIVES OF (3-OXO-3,4-DIHIDROQUINOXALIN-2-IL-AMINO) -BENZAMIDE AND RELATED COMPOUND, AS INHIBITORS OF GLUCOGENO FOSFORILASA FOR THE TREATMENT OF DIABETES AND OBESITY
AR043049A1 (en) HIDANTOINE DERIVATIVES, SAME PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION
YU48390B (en) NEW 2-ANYLINOPYRIMIDINE DERIVATIVES, A PROCEDURE FOR THEIR MANUFACTURING AND THE DESTINATION MEANS CONTAINING THESE DERIVATIVES
AR010310A1 (en) SUBSTITUTED PYRAZOLE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION, DRUGS UNDERSTANDING THEM, PROCEDURE FOR THEIR PRODUCTION, USE OF THE SAME FOR THE PRODUCTION OF DRUGS.
SV2006002126A (en) DERIVATIVES OF TETRAHYDROISOQUINOLILSULFONAMIDAS, ITS PREPARATION AND ITS USE IN THERAPEUTICS
CO5700772A2 (en) USEFUL PIRAZOLE COMPOSITIONS AS GSK-3 INHIBITORS
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
DE60307179D1 (en) UV radiation protective compositions
EA200100755A1 (en) 4-OXO-1,4-DIHYDRO-3-QUINOLINKARBOXAMIDES AS ANTI-VIRUS AGENTS
AR013358A1 (en) COMPOUNDS DERIVED FROM EPOTILONE (DERIVATIVES FROM AZA CICLOHEXADECANO), USEFUL IN THERAPEUTICS.
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
CO6190521A2 (en) DERIVATIVES OF AZACICLOALCANS AS INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA -9 DESATURASA
AR027744A1 (en) USEFUL DIFENILIC ETER COMPOUNDS IN THERAPY
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
AR060812A1 (en) MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN
AR060810A1 (en) MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DK0790987T3 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
ES2038678T3 (en) PROCEDURE FOR THE PREPARATION OF N- (2-ALQUIL-3-MERCAPTO-GLUTARIL) -ALFAMINO-ACIDOS.
UY32801A (en) NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0303449A2 (en) Substituted benzofuran-2-carboxamides derivatives
IS1726B (en) Similar methods for the production of androstenone derivative and intermediates used in the methods